This site is intended for healthcare professionals only
LoginRegister
Novartis concludes acquisition of Tourmaline BioUS Appeals Court decision favors MSN Pharma in Novartis heart drug Entresto generic dispute
Revise Phase III Trial Protocol for Roflumilast Cream: CDSCO Panel Tells Sun PharmaConduct phase III clinical study on resistant hypertension: CDSCO Panel tells Sun Pharmaceutical...
Zydus Bags USFDA Nod for Eltrombopag Tablets Across Four StrengthsZydus Lifscience gets CDSCO Panel nod to study Rabies Vaccine
CDSCO Expert Panel Backs Akums Faropenem Dispersible Tablets, Grants CT, BE WaiversAkum Drugs & Pharmaceutical gets CDSCO Panel nod for BE study of FDC Eplerenone plus Torsemide...
Jubilant Generics invests Rs 20 lakh in Jubilant Pharma CanadaLaurus Bio secures equity infusion of Rs 120 crore
Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 croreTeva to divest Teva-Takeda, its Business Venture in Japan
Zydus to commercialize Vascular Endothelial Growth Factor inhibitor Nufymco in USGilead Sciences, Tubulis ink pact to develop ADC candidate for select solid tumor target
Pfizer Slapped With Rs 8.79 Cr GST Demand Over Alleged ITC Irregularities, Plans AppealPfizer Gets CDSCO Panel Nod To Import 20 Valent Pneumococcal Conjugate Vaccine
Novartis declares positive results from phase III study for new malaria treatmentInclisiran be sold by retail under prescription of cardiologist only: CDSCO panel tells Novartis...
Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026Suven Pharma to acquire controlling stake in NJ Bio with investment of USD 64.4 million
Piramal Pharma gets 4 USFDA observations for Lexington facilityPiramal Pharma to pay USD 407400 to resolve dispute with VetDC
AstraZeneca to Invest USD 15 Billion in China by 2030AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer
X